A $70m boost has been secured by a Manchester-headquartered clinical-stage biopharmaceutical company, which is backed by a range of investors in the likes of Caffè Nero and Gulfstream.
F2G Ltd has received the backing from Forbion and Sofinnova Partners as well existing investors Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences.
The financing comes after the company recently agreed a $480m "strategic collaboration" with Shionogi & Co Ltd.